期刊文献+
共找到35篇文章
< 1 2 >
每页显示 20 50 100
Augmentative effect of tetrandrine on pentobarbital hypnosis mediated by 5-HT_(1A) and 5-HT_(2A/2C) receptors in mice 被引量:3
1
作者 杜楠 王黎恩 +4 位作者 师晓荣 崔翔宇 崔素颖 张帆 张永鹤 《Journal of Chinese Pharmaceutical Sciences》 CAS 2008年第3期192-196,共5页
It has been reported that augmentative effect of tetrandrine on pentobarbital hypnosis in mice may be related to serotonergic system. The present study was undertaken to investigate the interaction of tetrandrine and ... It has been reported that augmentative effect of tetrandrine on pentobarbital hypnosis in mice may be related to serotonergic system. The present study was undertaken to investigate the interaction of tetrandrine and different 5-HT receptors on pentobarbital-induced sleep by using the loss-of-righting reflex method. The results showed that augmentative effect of tetrandrine on pentobarbital hypnosis in mice were potentiated by the p-MPPI (5-HT1A receptor antagonist) (1 mg/kg, i.p.) and ketanserin (5-HT2A/2C receptor antagonist) (1.5 mg/kg, i.p.), respectively. Pretreatment with either 8-OH-DPAT (5-HT1A receptor agonist) (0.1 mg/kg, s.c.) or DOI (5-HT2A/2C receptor agonist) (0.2 mg/kg, i.p.) significantly decreased pentobarbital-induced sleep time, and tetrandrine (60 mg/kg, i.g.) significantly reversed this effect. These results suggest that both the 5-HTLA and 5-HT2A/2C subfamily may be involved in the potentiating mechanism of tetrandrine's effects on pantobarbital hypnosis. 展开更多
关键词 TETRANDRINE Pentobarbital hypnosis 5-ht1a receptor 5-ht2A/2C receptor
下载PDF
Targeted to medication-induced dyskinesia and tardive dyskinesia:A role of 5-HT_(1A) receptor
2
作者 ZHEN Xue-chu(State Key Drug Research Laboratory,Shanghai Institute of Materia Medica,Chinese Academy of Sciences,Shanghai 201203,China) 《沈阳药科大学学报》 CAS CSCD 北大核心 2008年第S1期56-56,共1页
Objective To outline the recent progress in drug discovery for medication-induced dyskinesia(Parkinson disease,PD)and tardive diskinesia(schizophrenia)with emphasizing the role of 5-HT1A receptor.Methods Development o... Objective To outline the recent progress in drug discovery for medication-induced dyskinesia(Parkinson disease,PD)and tardive diskinesia(schizophrenia)with emphasizing the role of 5-HT1A receptor.Methods Development of extrapyramidal syndrome(EPS)followed either chronic L-DOPA administration in PD(L-DOPA-induced dyskinesia,LID)or antipsychotic treatment in schizophrenia(Tardive dyskinesia,TD)remains a challenge in the clinical practice and drug discovery.In addition to the abnormal dopamine activity in the nigrostrial area that contributes to the LID or TD,recent information indicates that 5-HT1A receptor also plays an important role which is merging as promising target in treatment of LID or TD.Results l-Stepholidine(l-SPD),isolated from the Chinese herb Stephania,is known as a dual dopamine receptor agent(D1 receptor agonistic and D2 antagonistic activity).In addition,we further demonstrated that l-SPD binds to 5-HT1A receptor and exhibits a partial agonistic activity.In LID rat model,l-SPD not only attenuated the development of L-DOPA-induced dyskinesia(LID),but also relived the established LID.The effect of l-SPD on LID was completely blocked by pretreatment of 5-HT1A receptor antagonist,indicating the role of 5-HT1A receptor.Furthermore,we designed and synthesis a dual dopamine/5-HT1A receptor agonist MCL-135,which also exhibits a significant relief on LID while elicits its antiparkinsonian action.Conclusions 5-HT1A receptor plys an important role in the development of LID,targeted to dual dopamine/5-HT receptor may represent a promising strategy for drug design and discovery in LID and TD treatment. 展开更多
关键词 DYSKINESIA tardive dyskiesia 5-ht receptor agonist
下载PDF
Rivastigmine Restores 5-HT<sub>1A</sub>Receptor Levels in the Hippocampus of Olfactory Bulbectomized Mice
3
作者 Muhammad Rashedul Islam Shigeki Moriguchi +1 位作者 Hideaki Tagashira Kohji Fukunaga 《Advances in Alzheimer's Disease》 2014年第3期128-136,共9页
Rivastigmine, a dual acetylcholinesterase and butyrylcholinesterase inhibitor, is used for symptomatic treatment of patients with mild to moderately severe dementia in Alzheimer’s disease (AD) patients. In the presen... Rivastigmine, a dual acetylcholinesterase and butyrylcholinesterase inhibitor, is used for symptomatic treatment of patients with mild to moderately severe dementia in Alzheimer’s disease (AD) patients. In the present study, we found that 5-HT1A receptor (5-HT1AR) is downregulated, whereas 5-HT2A receptor (5-HT2AR) is upregulated in the hippocampal dentate gyrus (DG) and CA1 region by olfactory bulbectomy (OBX) in mice. Furthermore, chronic treatment with rivastigmine (1.0 mg/kg) for 2 weeks starting 2 weeks after OBX operation restored the decreased 5-HT1AR and the increased 5-HT2AR levels. To determine whether cholinergic receptor stimulation by rivastigmine is involved in the rivastigmine-induced regulation of 5-HTR levels, we treated the mice with mecamylamine (2.5 mg/kg), or atropine (5.0 mg/kg) with rivastigmine (1.0 mg/kg) once a day for 2 weeks. Notably, the rivastigmine-induced 5-HT1AR upregulation was eliminated by mecamylamine but not by atropine treatments. On the other hand, the restored 5-HT2AR level by rivastigmine was not affected by either mecamylamine or atropine. Treatment with 8-OH-DPAT, a selective 5-HT1AR agonist improved the decreased 5-HT1AR and the increased 5-HT2AR levels in OBX mice. On the other hand, treatment with TCB-2, a potent 5-HT2AR agonist had no effects on the 5-HT1AR and 5-HT2AR dysregulation in OBX mice. Taken together, nicotinic acetylcholine receptor (nAChR) stimulation mediates rivastigmine-induced upregulation of 5-HT1AR. Therefore, we speculate that the increased ACh levels by rivastigmine can stimulate nAChR located on serotonergic nerve terminals and stimulate 5-HT1AR by the enhanced 5-HT release in the hippocampus. The 5-HT1AR stimulation likely mediates the improvement of 5-HT1AR levels as auto-receptor in OBX hippocampus. 展开更多
关键词 RIVASTIGMINE 5-ht1a receptor 5-ht2A receptor NICOTINIC Acetylcholine receptor Olfactory Bulbectomized MICE
下载PDF
Effects of Activation and Blockade of Serotonin 5-HT1A Receptors on the Immune Response in Rats Selected for Different Levels of Aggressiveness
4
作者 Elizaveta Alperina Elena Zhukova +2 位作者 Galina Idova Rimma Kozhemyakina Margarita Cheido 《Pharmacology & Pharmacy》 2015年第9期451-459,共9页
The present study examines the effects of serotonin (5-HT) 1A receptor ligands on humoral im-mune response in two rat lines selected for over 75 generations for the enhancement or elimination of aggression. Activation... The present study examines the effects of serotonin (5-HT) 1A receptor ligands on humoral im-mune response in two rat lines selected for over 75 generations for the enhancement or elimination of aggression. Activation of presynaptic 5-HT1A receptors with a low dose of the selective 5-HT1A receptor agonist 8-OH-DPAT (0.1 mg/kg) or the blockade of postsynaptic 5-HT1A receptors with the antagonist WAY-100635 (1.0 mg/kg) did not affect the numbers of IgM-antibody forming cells (IgM-AFC) in the spleen of highly aggressive rats, which were characterized by higher immune responsiveness compared to nonaggressive line. On the other hand, the same doses of 8-OH-DPAT and WAY-100635, as well as a higher dose of 8-OH-DPAT (1.0 mg/kg), which is known to activate postsynaptic 5-HT1A receptors, produce immunostimulation in nonaggressive rats. However, only the highest dose of 8-OH-DPAT (5.0 mg/kg) was able to cause immunosuppression in nonaggressive rats that was mainly dependent on stimulation of postsynaptic 5-HT1A receptors. In contrast to nonaggressive rats, the dose of 1.0 mg/kg 8-OH-DPAT was sufficient to produce a decrease in the numbers of IgM-AFC in highly aggressive rats. Thus, pharmacological activation of pre- and postsynaptic 5-HT1A receptors, as well as the blockade of postsynaptic 5-HT1A receptors, produced different effects on the immune response in two lines of rats selected for high level of aggression or its absence. These data may have implications for more efficient treatments of a number of mental disorders associated with abnormal aggression. 展开更多
关键词 Aggressive Behavior SEROTONIN Pre- and POSTSYNAPTIC 5-ht1a receptors 8-OH-DPAT WAY-100635 IgM-Immune Response
下载PDF
S1-2 The 5-HT6 Receptor-Related Mechanism for the Cognition-Enhancing Properties of Hypidone Hydrochloride(YL-0919),A Novel Protential Antidepressant
5
作者 JIN Zeng-liang CHEN Xiao-fei +1 位作者 ZHANG Li-ming LI Yun-feng 《神经药理学报》 2018年第4期3-4,共2页
Hypidone hydrochloride(YL-0919),the 5-HT1A/6 agonists and 5-HT reuptake inhibitor,is a novel potent antidepressant with original chemical structure.Previous studies confirmed that YL-0919 has significant antidepressan... Hypidone hydrochloride(YL-0919),the 5-HT1A/6 agonists and 5-HT reuptake inhibitor,is a novel potent antidepressant with original chemical structure.Previous studies confirmed that YL-0919 has significant antidepressant-and anxiolytic-like effects.Compared with first-line antidepressants,YL-0919 possesses rapid-onset and cognition-enhancing advantages without causing sexual disorders.Recently,it has been found that it has high affinity with 5-HT6 receptor.Objective:To study the target characteristics of YL-0919 to 5-HT6 receptors,and to explore the relationship between the 5-HT6 receptor and the cognition-enhancing,antidepressant/anxiolytic-like effects of YL-0919 and targeting mechanisms.Methods:The radioligand binding inhibition test and[35S]-GTPγS binding assay were used to evaluate the binding affinity of YL-0919 to 5-HT6 receptor in rat striatum,transient CHO cell line and stable Hela cell lines.Novel object recognition(NOR),Morris water maze(MWM)and step-down test(SD)were used to evaluate the cognition-enhancing activity of YL-0919,and the selective 5-HT6 receptor antagonist SB271046 was used to evaluate the relationship between behavioral improvement caused by YL-0919 and 5-HT6 receptor activation.To study the 5-HT6 receptor related mechanisms of YL-0919,the competitive immunofluorescence assay were used to examine the cAMP level in h5-HT6 receptor-expressed in the Hela cells Results:①Radioligand competitive binding experiments showed that YL-0919 had high binding affinity with 5-HT6 receptors in the rat striatum,the CHO cells transiently expressed the h5-HT6 receptor and the Hela cells stably expressed the h5-HT6 receptor,with Ki of 10.72,14.76 and 28.12 nM respectively;[35S]-GTPγS showed full agonist characteristics of YL-0919 in striatum and cells,with EC50 of 71.23,64.73 and 52.92 nM respectively,and the maximum efficiency(Emax)reached 100%which is the same to the 5-HT6 receptor agonist WAY208466,suggesting that YL-0919 is a full 5-HT6 receptor agonist.②Cognitive-related behavioral tests showed that subchronic oral administration of YL-0919(1.25~2.5 mg·kg-1)could significantly increase the recognition index in NOR,the entries and duration in the target quadrant,the entries crossing the platform in WMW,shortened the first time crossing the platform in MWM and the step-down latency in SD,suggesting the cognitionenhancing effects of YL-0919;compared with Vilazodone,the partial agonist of 5-HT1A receptor and 5-HT reuptake inhibitor,which of no such functions;Further study showed that 5-HT6 receptor antagonist SB271046(10 mg·kg-1)completely blocked the cognition-enhancing effects of YL-0919 without affecting the cognitive activity itself,suggesting that 5-HT6 receptor activation might be its underlying mechanisms;③Mechanism study found that YL-0919 could significantly increase cAMP levels in the Hela cells stably-expressed the h5-HT6 receptor,which could be dose-dependent blocked by SB271046.Conclusion:YL-0919 is a full agonist of 5-HT6 receptor.YL-0919 showed significant cognition-enhancing effects in various kinds of animal models,and its underlying important mechanism might be activating 5-HT6 receptor.In addition,enhancing downstream cAMP-CREB signaling pathway of 5-HT6 receptor might at least partially mediate the above process.Moreover,5-HT6 receptor activation might also be one of the mechanisms of antidepressant-and anxiolytic-like effects of YL-0919.In conclusion,this study confirmed the 5-HT6 receptor-related mechanisms of YL-0919,the 1.1 types of antidepressants,laying the experimental foundation for developing novel antidepressants with cognition-enhancing effects. 展开更多
关键词 hypidone hydrochloride(YL-0919) 5-ht6 receptor agonist cognitionenhancing ANTIDEPRESSANT ANXIOLYTIC cAMP
下载PDF
5-羟色胺(5-HT)_(1A)受体配体的研究进展 被引量:3
6
作者 李鹏 杨日芳 +1 位作者 李锦 恽榴红 《中国药物化学杂志》 CAS CSCD 2008年第3期228-238,共11页
5-羟色胺(5-HT)是重要的神经递质,5-HT受体(5-HTR)在认知、情感等众多神经活动中发挥着重要作用,是重要的药物靶标。5-HT1A受体(5-HT1AR)是众多5-HTR亚型中研究最为广泛和深入的一类受体,研究5-HT1A受体配体(5-HT1ARL)对于临床上治疗焦... 5-羟色胺(5-HT)是重要的神经递质,5-HT受体(5-HTR)在认知、情感等众多神经活动中发挥着重要作用,是重要的药物靶标。5-HT1A受体(5-HT1AR)是众多5-HTR亚型中研究最为广泛和深入的一类受体,研究5-HT1A受体配体(5-HT1ARL)对于临床上治疗焦虑、抑郁、疼痛等疾病都具有重要的价值。该文主要从5-HT1ARL结构类型的角度综述5-HT1ARL的最新研究进展,并简要介绍定向多靶标配体的研究成果,展望5-HT1ARL药物的开发前景。 展开更多
关键词 5-羟色胺 5-ht1a受体 5-ht1a受体配体 激动剂 拮抗剂 定向多靶标配体
下载PDF
5-HT_(1A)受体激动剂类抗抑郁药的研究与开发 被引量:8
7
作者 陈芳萍 李运曼 刘国卿 《药学进展》 CAS 2003年第4期213-216,共4页
综述5-HT1A-受体激动剂抗抑郁作用的机制及其新产品的研究与开发。5-HT1A受体激动剂通过激动突触后膜 的5-HT1A受体,负反馈抑制海马5-HT能神经元上的自主受体而发挥抗抑郁作用,克服了传统抗抑郁药的滞后效应。
关键词 5-ht1a受体激动剂 抗抑郁药 作用机制 氟斑色林 Vilazodone SLV-308
下载PDF
新型5-HT_(1A)受体激动和5-HT重摄取抑制双重活性化合物YL-0919抗抑郁作用的行为学评价 被引量:6
8
作者 李恺 陈红霞 +5 位作者 袁莉 张黎明 王伊文 张有志 杨日芳 李云峰 《国际药学研究杂志》 CAS 2010年第5期366-371,共6页
目的研究兼有5-HT1A受体激动和5-HT重摄取抑制双重活性化合物YL-0919的抗抑郁作用。方法分别采用小鼠悬尾实验、小鼠强迫游泳实验、小鼠自发活动实验和大鼠获得性无助模型,观察不同剂量(0.625、1.25、2.5和5mg/kg)YL-0919的抗抑郁作... 目的研究兼有5-HT1A受体激动和5-HT重摄取抑制双重活性化合物YL-0919的抗抑郁作用。方法分别采用小鼠悬尾实验、小鼠强迫游泳实验、小鼠自发活动实验和大鼠获得性无助模型,观察不同剂量(0.625、1.25、2.5和5mg/kg)YL-0919的抗抑郁作用。结果在小鼠悬尾实验和小鼠强迫游泳实验中,单次灌胃给予YL-0919(0.625~2.5mg/kg)能够显著缩短小鼠悬尾不动时间和游泳不动时间;在小鼠自发活动实验中,YL-0919在上述剂量范围对自发活动无影响;在大鼠获得性无助模型上,灌胃给予YL-0919〔0.625~1.25mg/(kg·d),1~4d〕能显著减少逃避失败次数。结论 YL-0919在小鼠和大鼠模型上具有明确的抗抑郁活性,并且在抗抑郁的有效剂量范围内无中枢兴奋和抑制作用,具有成为新型抗抑郁药物的研发潜力。 展开更多
关键词 抑郁症 抗抑郁药 5-ht1a受体激动剂 5-ht重摄取抑制 YL-0919
下载PDF
New 3-(4-arylpiperazin-1-yl)-1-(benzo[b]thiophen-3-yl)-2-methylpropanol derivatives:Synthesis and evaluation for dual 5-HT1A/SSRI activities 被引量:1
9
作者 Ai Jun Li Xiao Hua Zhang +1 位作者 Xue Qin Zhou Dong Zhi Liu 《Chinese Chemical Letters》 SCIE CAS CSCD 2008年第4期412-414,共3页
A series of 3-(4-arylpiperazin-1-yl)-1-(benzo[b]thiophen-3-yl)-2-methylpropanol derivatives were designed and synthesized based on 5-HT1A/SSRI drugs design strategies.The synthesized compounds were evaluated for t... A series of 3-(4-arylpiperazin-1-yl)-1-(benzo[b]thiophen-3-yl)-2-methylpropanol derivatives were designed and synthesized based on 5-HT1A/SSRI drugs design strategies.The synthesized compounds were evaluated for their dual 5-HT1A/5-HTT activities. 展开更多
关键词 Antidepressants ARYLPIPERAZINES 5-ht1a/SSRI 5-ht transporter 5-ht1a receptor
下载PDF
N-(2-(2-Methoxyphenylthio)benzyl)-2-aryloxyethylamines:Synthesis and evaluation for dual 5-HT_(1A)/SSRI activities 被引量:1
10
作者 Xue Dan Wu Dong Zhi Liu +1 位作者 Ai Jun Li Xue Qin Zhou 《Chinese Chemical Letters》 SCIE CAS CSCD 2008年第3期295-298,共4页
The design, synthesis and biological evaluation of N-(2-(2-methoxyphenylthio) benzyl)-2-aryloxyethyl amines with dual 5-HT1A/SSR/activities are reported. Compound 8e displays the best dual activities and is a prom... The design, synthesis and biological evaluation of N-(2-(2-methoxyphenylthio) benzyl)-2-aryloxyethyl amines with dual 5-HT1A/SSR/activities are reported. Compound 8e displays the best dual activities and is a promising lead compound for further SAR studies. 展开更多
关键词 Antidepressants 5-ht1a/5-htT 5-ht1a receptor Diphenylsulfide Aryloxyethylamines
下载PDF
Arylpiperazine derivatives of diphenylsulfide:Synthesis and evaluation for dual 5-HT_(1A)/SSRI activities 被引量:1
11
作者 Xue Dan Wu Dong Zhi Liu +1 位作者 Ai Jun Li Xue Qin Zhou 《Chinese Chemical Letters》 SCIE CAS CSCD 2008年第3期291-294,共4页
The design, synthesis and biological evaluation of a novel series of arylpiperazine derivatives of diphenylsulfide with dual 5- HT1A/SSRI activities are reported. The target compounds exhibit low to moderate 5-HT tran... The design, synthesis and biological evaluation of a novel series of arylpiperazine derivatives of diphenylsulfide with dual 5- HT1A/SSRI activities are reported. The target compounds exhibit low to moderate 5-HT transporter affinity and moderate to high 5- HT1A affinity, Compound 13a shows moderate dual activities and is a promising lead compound for further structure-activity relationships studies. 展开更多
关键词 Antidepressants 5-ht1a/SSRI ARYLPIPERAZINES 5-ht1a receptor Diphenylsulfide
下载PDF
1-[2-(2-Methoxyphenylthio) benzyl]-4-arylpiperazines derivatives:Synthesis and evaluation for dual 5-HT_(1A)/SSRI activities 被引量:1
12
作者 Xin Wang Dong Zhi Liu Ai Jun Li 《Chinese Chemical Letters》 SCIE CAS CSCD 2008年第1期37-39,共3页
A series of 1-[2-(2-methoxyphenylthio) benzyl]-4-arylpiperazines derivatives was designed and synthesized based on 5-HT1A/ SSRI drugs design strategies. The synthesized compounds were evaluated for their dual 5-HT1A... A series of 1-[2-(2-methoxyphenylthio) benzyl]-4-arylpiperazines derivatives was designed and synthesized based on 5-HT1A/ SSRI drugs design strategies. The synthesized compounds were evaluated for their dual 5-HT1A/5-HTT activities. 2007 Ai Jun Li. Published by Elsevier B.V. on behalf of Chinese Chemical Society. All rights reserved. 展开更多
关键词 Antidepressants 5-ht1a/5-htT Serotonin transporter 5-ht1a receptor Diphenylsulfide
下载PDF
1-(N-(2-(2-Methoxyphenylthio)benzyl)-N-methylamino-3-aryloxypropan-2-ols:Synthesis and evaluation for dual 5-HT_(1A)/SSRI activities 被引量:1
13
作者 Xin Wang Dong Zhi Liu Ai Jun Li 《Chinese Chemical Letters》 SCIE CAS CSCD 2008年第1期40-42,共3页
A series of 1-(N-(2-(2-methoxyphenylthio)benzyl)-N-methylamino-3-aryloxypropan-2-ols derivatives were designed and synthesized based on 5-HT1A/SSRI drugs design strategies. The synthesized compounds were evaluate... A series of 1-(N-(2-(2-methoxyphenylthio)benzyl)-N-methylamino-3-aryloxypropan-2-ols derivatives were designed and synthesized based on 5-HT1A/SSRI drugs design strategies. The synthesized compounds were evaluated for their dual 5-HT1A/ 5-HTT activities. 2007 Ai Jun Li. Published by Elsevier B.V. on behalf of Chinese Chemical Society. All rights reserved. 展开更多
关键词 5-ht1a/SSRI Serotonin transporter 5-ht1a receptor Diphenylsulfide
下载PDF
Inhibition of 5-HT_3 Receptors-activated Currents by Cannabinoids in Rat Trigeminal Ganglion Neurons
14
作者 石波 杨蓉 +6 位作者 王晓慧 刘海霞 邹丽 胡晓群 吴建萍 邹安若 刘玲华 《Journal of Huazhong University of Science and Technology(Medical Sciences)》 SCIE CAS 2012年第2期265-271,共7页
This study investigated the modulatory effect of synthetic cannabinoids WIN55,212-2 on 5-HT3 receptor-activated currents (I5-HT3) in cultured rat trigeminal ganglion (TG) neurons using whole-cell patch clamp technique... This study investigated the modulatory effect of synthetic cannabinoids WIN55,212-2 on 5-HT3 receptor-activated currents (I5-HT3) in cultured rat trigeminal ganglion (TG) neurons using whole-cell patch clamp technique. The results showed that: (1) The majority of examined neurons (78.70%) were sensitive to 5-HT (3–300 μmol/L). 5-HT induced inward currents in a concentration-dependent manner and the currents were blocked by ICS 205-930 (1 μmol/L), a selective antagonist of the 5-HT3 receptor; (2) Pre-application of WIN55,212-2 (0.01–1 μmol/L) significantly inhibited I5-HT3 reversibly in concentration-dependent and voltage-independent manners. The concentra-tion-response curve of 5-HT3 receptor was shifted downward by WIN55,212-2 without any change of the threshold value. The EC50 values of two curves were very close (17.5±4.5) mmol/L vs. (15.2±4.5) mmol/L and WIN55,212-2 decreased the maximal amplitude of I5-HT3 by (48.65±4.15)%; (3) Neither AM281, a selective CB1 receptor antagonist, nor AM630, a selective CB2 receptor antagonist reversed the inhibition of I5-HT3 by WIN55,212-2; (4) When WIN55,212-2 was given from 15 to 120 s before 5-HT application, inhibitory effect was gradually increased and the maximal inhibition took place at 90 s, and the inhibition remained at the same level after 90 s. We are led to concluded that-WIN55,212-2 inhibited I5-HT3 significantly and neither CB1 receptor antagonist nor CB2 receptor antagonist could reverse the inhibition of I5-HT3 by WIN55,212-2. Moreover, WIN55,212-2 is not an open channel blocker (OCB) of 5-HT3 receptor. WIN55,212-2 significantly inhibited 5-HT-activated currents in a non-competitive manner. The inhibition of I5-HT3 by WIN55,212-2 is probably new one of peripheral analgesic mechanisms of WIN55,212-2, but the mechanism by which WIN55,212-2 inhibits I5-HT3 warrants further investigation. 展开更多
关键词 WIN55 212-2 5-ht3 receptor CB1 receptor CB2 receptor trigeminal ganglion neuron whole-cell patch clamp
下载PDF
Systems pharmacology modeling in neuroscience: Prediction and outcome of PF-04995274, a 5-HT4 partial agonist, in a clinical scopolamine impairment trial
15
作者 Timothy Nicholas Sridhar Duvvuri +8 位作者 Claire Leurent David Raunig Tracey Rapp Phil Iredale Carolyn Rowinski Robert Carr Patrick Roberts Athan Spiros Hugo Geerts 《Advances in Alzheimer's Disease》 2013年第3期83-98,共16页
Background: 5-HT4receptors in cortex and hippocampus area are considered as a possible target for modulation of cognitive functions in Alzheimer’s disease (AD). A systems pharmacology approach was adopted to evaluate... Background: 5-HT4receptors in cortex and hippocampus area are considered as a possible target for modulation of cognitive functions in Alzheimer’s disease (AD). A systems pharmacology approach was adopted to evaluate the potential of the 5-HT4 modulation in providing beneficialeffects on cognition in AD. Methods: A serotonergic synaptic cleft model was developed by integrating serotonin firing, release, synaptic half-life, drug/tracer properties (affinity and agonism) as inputs and5-HT4 activity as output. The serotonergic model was calibrated using bothinvivo data on free 5-HT levels in preclinical models and human imaging data. The model was further expanded to other neurontransmitter systems and incorporated into a computer-based cortical network model which implemented the physiology of 12 different membrane CNS targets. A biophysically realistic, multi-compartment model of 80 pyramidal cells and 40 interneurons was further calibrated usingdata reported for working memory tasks in healthyhumans and schizophrenia patients. Model output was the duration of the network firing activity in response to an external stimulus. Alzheimer’s disease (AD) pathology, in particular synapse and neuronal cell loss in addition to cholinergic deficits, was calibrated to align with the natural clinical disease progression. The model was used to provide insights into the effect of 5-HT4 activation on working memory and to prospectively simulate the response of PF- 04995274, a 5-HT4partial agonist, in a scopolamine-reversal trial in healthy human subjects. Results: The model output suggested a beneficial effect of 5-HT4 agonism on working memory. The model also projected no effect or an exacerbation of scopolamine impairment for low in- trinsic activity 5-HT4agonists, which was supported by the subsequent human trial outcome. The clinical prediction of the disease model strongly suggests that 5-HT4 agonists with high intrinsic activity may have a beneficial effect on cognition in AD patients. 展开更多
关键词 SYSTEMS PHARMACOLOGY 5-ht4 receptor Partial agonist Scopolamine-Reversal
下载PDF
Molecular signaling of 5-HT<sub>1A</sub>and presence of serotonergic cells in the fetal cerebral cortex
16
作者 Alfonso B. M. de Oca Gabriel M. Gutiérrez Jorge H. Rodríguez 《World Journal of Neuroscience》 2013年第2期76-82,共7页
Early appearance of the serotonergic system in the fetal brain and the various effects of serotonin (5-HT) on brain morphogenesis, have given support to a neurotrophic role of serotonin. This function of serotonin is ... Early appearance of the serotonergic system in the fetal brain and the various effects of serotonin (5-HT) on brain morphogenesis, have given support to a neurotrophic role of serotonin. This function of serotonin is accomplished through a system of serotonin nerve terminals in the target regions that involves various 5-HT receptors. In visual, auditory and somatosensory cortex an early and intense serotonergic innervation is particularly important. The neuronal somata of these terminals are normally located in the mesencephalon and they have not been observed in the maturing cerebral cortex, neither in the adult brain. By using immunolabeling techniques, fluorescence and confocal microscopy, we observe the presence of both, 5-HT terminals and 5-HT cells in mesencephalon (Me, E17) and in the neopallium (Np, E13-E16) cocultures. Cells immunopositive to 5-HT and to tryptophan-5-hydroxilase are also observed in the Np on day 12 of culture. These results concerning the unexpected presence of serotonergic cells in the fetal cerebral cortex are interesting and may be of importance in corticogenesis. As it happens with other elements of the serotonergic system, the presence of these phenotypically serotonergic cells in the early cerebral cortex may be transitory and probably supporting cortex maturation processes. The molecular signaling path of the 5-HT1A receptor has also been identified. 展开更多
关键词 SEROTONERGIC System SEROTONIN receptor 5-ht1a Molecular Signaling Paths
下载PDF
5-羟色胺1A受体激动剂治疗遗传性小脑共济失调的Meta分析 被引量:6
17
作者 毛旭强 张剑平 +2 位作者 程卫国 于璇 李在望 《神经损伤与功能重建》 2012年第1期40-43,共4页
目的:了解5-羟色胺1A(5-HT1A)受体激动剂治疗遗传性小脑共济失调的有效性。方法:根据入选标准收集文献;依据Meta分析方法,应用RevMan 4.3.2软件计算5-HT1A受体激动剂治疗组和安慰剂对照组改善小脑功能评分的标准化均数差(SMD)及95%的可... 目的:了解5-羟色胺1A(5-HT1A)受体激动剂治疗遗传性小脑共济失调的有效性。方法:根据入选标准收集文献;依据Meta分析方法,应用RevMan 4.3.2软件计算5-HT1A受体激动剂治疗组和安慰剂对照组改善小脑功能评分的标准化均数差(SMD)及95%的可信区间(CI)。结果:5-HT1A受体激动剂治疗组与安慰剂对照组改善小脑功能评分的SMD及95%CI分别为-0.36,(-2.29,1.59);2组疗效无显著性差异(Z=0.36,P=0.359)。结论:目前的临床资料尚不能证实5-HT1A受体激动剂能有效改善遗传性小脑共济失调症状。 展开更多
关键词 5-羟色胺1a受体激动剂 遗传性小脑共济失调 META分析
下载PDF
5-羟色胺1A受体激动剂高通量筛选模型的建立 被引量:4
18
作者 孙颖 蔡海燕 +3 位作者 沈敬山 朱维良 王贺瑶 郭敏亮 《中国药理学通报》 CAS CSCD 北大核心 2012年第5期731-736,共6页
目的为发现5-羟色胺1A(5-HT1A)受体的激动剂,通过报告基因活性检测的方法建立高通量筛选(HTS)细胞模型。方法将带有人源5-HT1A受体的真核表达质粒pcD-NA3.1(pcDNA3.1-h5-HT1AR)与带有报告基因pCRE-luc的pcDNA3.1质粒(pcDNA3.1-pCRE-luc... 目的为发现5-羟色胺1A(5-HT1A)受体的激动剂,通过报告基因活性检测的方法建立高通量筛选(HTS)细胞模型。方法将带有人源5-HT1A受体的真核表达质粒pcD-NA3.1(pcDNA3.1-h5-HT1AR)与带有报告基因pCRE-luc的pcDNA3.1质粒(pcDNA3.1-pCRE-luc)共转染到工具细胞中,通过对工具细胞选择、共转染质粒比例、化合物孵育时间及阳性化合物选择等条件进行探索和优化,建立了稳定表达人源5-HT1A受体并可用于该受体激动剂筛选的细胞模型(HEK293-h5-HT1AR)。结果①根据瞬转实验中信号值的高低,模型采用HEK293细胞作为工具细胞;②根据瞬转实验中的信噪比,发现pcDNA3.1-h5-HT1AR:pcDNA3.1-pCRE-luc的最佳比例为1∶3;③对化合物孵育时间进行优化,选择的最佳孵育时间为6 h;④阳性化合物的选择过程中,实验研究了5-HT.HCl,Flibanserin,8-OH-DPAT以及Lorcaser-in(APD356)4个已报道有5-HT1A受体激动活性的化合物,结果表明APD356在该体系中最适合作为阳性对照化合物。⑤该细胞株连续培养12代,信号稳定。结论通过对一系列实验条件进行选择和优化,建立了一个稳定表达人源5-HT1A受体的细胞模型,该模型可用于高通量5-HT1A激动剂的筛选。 展开更多
关键词 激动剂 高通量筛选 5-羟色胺1a受体 抑郁症 内源型 细胞稳转株
下载PDF
Insights into the discovery of new 5-HT1A receptor ligands:receptor based pharmacophore 被引量:1
19
作者 杨志瑜 吕炜 +2 位作者 田然 金宏威 曾慧慧 《Journal of Chinese Pharmaceutical Sciences》 CAS 2009年第2期151-155,共5页
5-HT1A receptor is a crucial therapeutic target for the treatment of anxiety, depression, pain, etc. Design and preparation of potent 5-HT1A receptor ligands for drug discovery has attracted extensive attention in the... 5-HT1A receptor is a crucial therapeutic target for the treatment of anxiety, depression, pain, etc. Design and preparation of potent 5-HT1A receptor ligands for drug discovery has attracted extensive attention in the past few years. In this paper, a three dimensional model of human 5-HT1A receptor was constructed by means of homology modeling. And the docking of MP349 to the receptor suggested a reliable binding mode for 5-HT1A receptor ligand. Based on this ligand-receptor binding mode, an elaborate receptor structure based pharmacophore model was established, which revealed many important features responsible for ligand and 5-HT1A receptor interactions. A virtual screening experiment verified the ability of this pharmacophore model to discover true 5-HT1A receptor ligand. The results of this research would provide important information for further optimizations of 5-HT1A receptor ligands and guide related new lead discoveries. 展开更多
关键词 5-ht1a receptor Homology modeling DOCKING PHARMACOPHORE Virtual screening
原文传递
二甲双胍联合利拉鲁肽治疗超重多囊卵巢综合征患者后MFAP5水平变化与临床指标改善的相关性研究 被引量:10
20
作者 李蔚鑫 李行 +6 位作者 廖明钰 石榴 张玉玲 彭桂亮 洪翩 隆敏 郑宏庭 《陆军军医大学学报》 CAS CSCD 北大核心 2022年第3期217-223,共7页
目的通过分析血浆微纤丝相关蛋白5(microfibrillar associated protein 5,MFAP5)水平变化与代谢指标改善的相关性,研究MFAP5在二甲双胍联合胰高血糖素样肽-1受体激动剂(glucagon-like peptide-1 receptor agonist,GLP-1RA)利拉鲁肽治疗... 目的通过分析血浆微纤丝相关蛋白5(microfibrillar associated protein 5,MFAP5)水平变化与代谢指标改善的相关性,研究MFAP5在二甲双胍联合胰高血糖素样肽-1受体激动剂(glucagon-like peptide-1 receptor agonist,GLP-1RA)利拉鲁肽治疗超重多囊卵巢综合征(polycystic ovary syndrome,PCOS)患者中的潜在作用及机制。方法收集23例经我院二甲双胍联合利拉鲁肽方案治疗12周的超重或肥胖型PCOS患者的病历资料,根据体质指数(BMI)将受试者分为肥胖组(n=12)和超重组(n=11)2个亚组。口服盐酸二甲双胍肠溶片0.5 g,3次/d;皮下注射利拉鲁肽注射液0.6 mg,1次/d,1周后增加至1.2 mg,1次/d,最大剂量增至1.8 mg,1次/d。对比两组治疗前和治疗12周后的体格测量指标、代谢及炎症相关指标、性激素水平以及血浆MFAP5水平。结果经过12周的治疗,2组患者体格测量指标及糖脂代谢指标、炎症指标、性激素水平均有改善(P<0.05);相关性分析提示,所有患者血浆MFAP5水平变化值与体质量(r=0.520,P=0.011)、BMI(r=0.469,P=0.024)、腰围(r=0.634,P=0.001)、臀围(r=0.587,P=0.001)、空腹胰岛素(r=0.602,P=0.002)、甘油三酯(TG,r=0.556,P=0.002)的变化值呈正相关;亚组分析提示,超重组血浆MFAP5水平变化值与糖脂代谢相关指标[胰岛素释放试验60 min胰岛素(r=0.602,P=0.002)、TG(r=0.655,P=0.029)]的变化值呈正相关;肥胖组患者血浆MFAP5水平变化值与腰围(r=0.495,P=0.002)、臀围(r=0.508,P=0.010)、糖脂代谢相关指标[空腹胰岛素(r=0.578,P=0.001)、胰岛素释放试验180 min胰岛素(r=0.656,P=0.021)、HOMA-IR(r=0.497,P=0.012)、TG(r=0.595,P=0.041)]、性激素水平[促黄体生成素(r=0.468,P=0.042)]的变化值呈正相关。结论超重PCOS患者血浆MFAP5水平可能与糖脂代谢的改善有关;MFAP5可能是参与二甲双胍联合利拉鲁肽治疗超重PCOS过程中的相关分子,可能作为超重PCOS治疗效果监测的可靠指标。 展开更多
关键词 二甲双胍 胰高血糖素样肽-1受体激动剂 利拉鲁肽 超重多囊卵巢综合征 糖脂代谢 微纤丝相关蛋白5
下载PDF
上一页 1 2 下一页 到第
使用帮助 返回顶部